Paricalcitol Injection Phase II Trial

Study Identifier
J-ZEM-05-002
CT.gov Identifier
NCT00646932
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Kidney Disease
    • Study Drug
  • paricalcitol
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    20 - 74 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure
    Exclusion Criteria:
    - Subject is considered by investigator, for any reason, to be an unsuitable candidate for the study

    Protocol Summary

    The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks

    (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3

    times a week for stable chronic renal failure.

    Study Locations

    Location
    Status
    Location
    Gunma, Japan
    Status
    Not applicable
    Location
    Hokkaido, Japan
    Status
    Not applicable
    Location
    Ibaraki, Japan
    Status
    Not applicable
    Location
    Kagoshima, Japan
    Status
    Not applicable
    Location
    Kumamoto, Japan
    Status
    Not applicable
    Location
    Nagano, Japan
    Status
    Not applicable
    Showing {first} - {last} of {total} Results